In response to the novel coronavirus disease 2019 (COVID-19) crisis, the Food and Drug Administration (FDA), via its Emergency Use Authorization (EUA) authority, initially provided, and then revoked, authorization for use of hydroxychloroquine for treating patients with COVID-19. This process was politically and scientifically contentious and illustrates central problems that can arise with emergency drug authorizations during crises. These problems include the authorization of potentially ineffective or unsafe therapeutics, the appearance of nonexpert political advocacy generating public pressure for product authorizations with questionable safety and efficacy, and the imposition of significant costs on the health of the public and on the credibility and influence of regulatory agencies such as the FDA.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Kyle Thomson, JD, MPH, American Medical Association, 25 Massachusetts Ave NW, Ste 600, Washington, DC 20001 (email@example.com).
Published Online: August 31, 2020. doi:10.1001/jama.2020.16253
Conflict of Interest Disclosures: Mr Thomson reported being associate chief counsel in the Office of the Chief Counsel of the FDA from 2012 to 2020. No other disclosures were reported.
Disclaimer: The views, thoughts, and opinions expressed in this article are solely those of the authors and do not necessarily reflect the authors’ employers.
You currently have no searches saved.
You currently have no courses saved.